The American Cancer Society’s annual report approximates the new cancer diagnoses and deaths expected in 2021 and identifies impactful patterns in oncology care.
he designation is supported by data from a phase 1 trial conducted by Reata Pharmaceuticals in 2016. Findings from the study showed 44% of patients treated with berubicin (n=11 out of 25) experienced a statistically significant improvement in progression free survival.
For patients with glioblastoma, short delays in the initiation of chemoradiotherapy after surgery were not linked to worse survival — yet initiation too soon was.
[Cancer Management and Research] A review of past and ongoing trials using ipilimumab-nivolumab combination therapy for metastatic renal cell carcinoma.